HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA semi-annual agenda

This article was originally published in The Rose Sheet

Executive Summary

Oral care products that claim to reduce or prevent dental plaque and gingivitis are expected to be addressed by a notice of proposed rulemaking in May 2007, while timetables for final actions related to skin-bleaching products containing hydroquinone and the prohibition of certain cattle material in human food and cosmetics have yet to be determined, according to FDA's semi-annual agenda, which appeared in the Dec. 11 Federal Register. The agency had targeted December 2006 for a notice of proposed rulemaking on UVA/UVB sunscreens, having postponed the measure previously (1"The Rose Sheet" May 23, 2005, In Brief). An advance notice of proposed rulemaking for combination sunscreen-and-insect-repellant OTC products was also slated for release last month...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel